Clinical Importance of miRNA in Diabetic Neuropathy: Pathophysiology, Diagnosis, and Therapeutic Potential.

Abstract readReview

In one paragraph

Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Extracellular Vesicle-Associated microRNAs as Candidate Biomarkers and Mediators of Diabetic Complications: Clinical and Translational Evidence Across Neuropathy, Diabetic Kidney Disease, Retinopathy, and MASLD.Metabolites · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Desh Deepak SinghAmity Institute of Biotechnology, Amity University Rajasthan, Jaipur, 303002, India.ORCID 0000-0003-2967-8838

Funding

Department of Science & Technology, Government of India SR/FIST/LS-1/2019/502DST-PURSE SR/PURSE/2021/77

6 · The paper itself

Abstract

Diabetic Neuropathy (DN) is the major chronic complication in diabetic patients. The exact pathophysiological mechanisms of DN are not fully understood; however, failures in axon- Schwann cell and microvascular endothelial communication networks play major roles in DN progression. The multiple pathophysiological mechanisms of DN are regulated by microRNAs (miRNAs), including inflammation, vascularization, angiogenesis, posttranscriptional regulation, intercellular communication, and signalling pathways. Various types of miRNA affect the gene expressions within cells, but their profiles often change during DN, including SMAD, PI3K, Nuclear Factor kappa B (NF-κB), and MAPK. DN has been associated with the miRNAs-9, miRNA-106, miRNA-182, miRNA-23a, miRNA-23b, miRNA-23c, miRNA-503, miRNA-203, miRNA-145, and miRNA-126. MiRNA dysregulation is one of the first molecular changes seen in diabetics. Therefore, miRNAs hold promise as both therapeutic targets and diagnostic biomarkers. This study aims to discuss the importance of miRNA in clinical pathophysiology, diagnosis, signalling pathways, and therapeutic targets for DN.

Indexed as

Diabetic NeuropathiesMicroRNAsAnimalsBiomarkersClinical RelevanceGene Expression RegulationHumansSignal TransductionBiomarkersMicroRNAsDiabetic neuropathymicroRNAmicrovascular endothelial communication networksneurodegenerative diseaseneurovascular dysfunctionpathophysiologytherapeutic potential

Identifiers

PMID40993953

DOI10.1016/j.biopha.2025.117959

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.